Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -15.17 Million USD | -46.75% |
| 2021 | -11.73 Million USD | -10.25% |
| 2020 | -10.63 Million USD | 2.79% |
| 2019 | -10.94 Million USD | 32.13% |
| 2018 | -16.12 Million USD | -121.52% |
| 2017 | 74.94 Million USD | 623.79% |
| 2016 | -14.3 Million USD | 48.09% |
| 2015 | -27.56 Million USD | 22.85% |
| 2014 | -35.72 Million USD | 16.33% |
| 2013 | -42.69 Million USD | -46.45% |
| 2012 | -29.15 Million USD | -619.46% |
| 2011 | 5.61 Million USD | 111.23% |
| 2010 | -49.96 Million USD | -26.16% |
| 2009 | -39.6 Million USD | -666.63% |
| 2008 | -5.16 Million USD | -1.53% |
| 2007 | -5.08 Million USD | -7.32% |
| 2006 | -4.74 Million USD | 3.81% |
| 2005 | -4.92 Million USD | -39.2% |
| 2004 | -3.54 Million USD | -96.83% |
| 2003 | -1.79 Million USD | 39.3% |
| 2002 | -2.96 Million USD | -19920.27% |
| 2001 | 14.95 Thousand USD | -99.19% |
| 2000 | 1.83 Million USD | 144.08% |
| 1999 | -4.17 Million USD | 85.11% |
| 1998 | -28.03 Million USD | -20.59% |
| 1997 | -23.24 Million USD | -10.86% |
| 1996 | -20.96 Million USD | -94.16% |
| 1995 | -10.8 Million USD | 0.0% |
| 1994 | -10.8 Million USD | -35.0% |
| 1993 | -8 Million USD | -207.69% |
| 1992 | -2.6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | 6.03 Million USD | 860.17% |
| 2023 Q1 | -793.48 Thousand USD | 85.63% |
| 2023 Q3 | -2.25 Million USD | -137.39% |
| 2022 Q3 | -5.7 Million USD | -90.3% |
| 2022 Q4 | -5.52 Million USD | 3.28% |
| 2022 FY | -17.21 Million USD | -46.75% |
| 2022 Q1 | -2.99 Million USD | 17.99% |
| 2022 Q2 | -2.99 Million USD | -0.14% |
| 2021 Q3 | -2.43 Million USD | 8.83% |
| 2021 Q4 | -3.65 Million USD | -49.81% |
| 2021 Q2 | -2.67 Million USD | 9.87% |
| 2021 FY | -11.73 Million USD | -10.25% |
| 2021 Q1 | -2.96 Million USD | -5.09% |
| 2020 Q4 | -2.82 Million USD | 2.63% |
| 2020 FY | -10.63 Million USD | 2.79% |
| 2020 Q1 | -2.67 Million USD | 3.54% |
| 2020 Q2 | -2.32 Million USD | 13.02% |
| 2020 Q3 | -2.89 Million USD | -24.67% |
| 2019 Q1 | -2.42 Million USD | 23.44% |
| 2019 FY | -10.94 Million USD | 32.13% |
| 2019 Q4 | -2.77 Million USD | 9.83% |
| 2019 Q3 | -3.07 Million USD | -15.0% |
| 2019 Q2 | -2.67 Million USD | -10.05% |
| 2018 FY | -16.12 Million USD | -121.52% |
| 2018 Q4 | -3.17 Million USD | 16.98% |
| 2018 Q3 | -3.82 Million USD | -59.63% |
| 2018 Q2 | -2.39 Million USD | 64.47% |
| 2018 Q1 | -6.73 Million USD | -66.04% |
| 2017 Q3 | -1.38 Million USD | 73.22% |
| 2017 Q4 | -4.05 Million USD | -192.06% |
| 2017 Q2 | -5.18 Million USD | -106.06% |
| 2017 FY | 74.94 Million USD | 623.79% |
| 2017 Q1 | 85.58 Million USD | 2304.67% |
| 2016 Q2 | -6.68 Million USD | -81.26% |
| 2016 FY | -14.3 Million USD | 48.09% |
| 2016 Q4 | -3.88 Million USD | -6437.56% |
| 2016 Q3 | -59.37 Thousand USD | 99.11% |
| 2016 Q1 | -3.68 Million USD | -46.85% |
| 2015 FY | -27.56 Million USD | 22.85% |
| 2015 Q4 | -2.51 Million USD | 68.9% |
| 2015 Q2 | -9.69 Million USD | -32.9% |
| 2015 Q3 | -8.07 Million USD | 16.71% |
| 2015 Q1 | -7.29 Million USD | -6.21% |
| 2014 Q3 | -6.89 Million USD | 32.51% |
| 2014 Q2 | -10.22 Million USD | 12.93% |
| 2014 FY | -35.72 Million USD | 16.33% |
| 2014 Q1 | -11.74 Million USD | 14.63% |
| 2014 Q4 | -6.86 Million USD | 0.49% |
| 2013 FY | -42.69 Million USD | -46.45% |
| 2013 Q4 | -13.75 Million USD | -21.63% |
| 2013 Q2 | -10.3 Million USD | -40.31% |
| 2013 Q3 | -11.3 Million USD | -9.77% |
| 2013 Q1 | -7.34 Million USD | -1.47% |
| 2012 FY | -29.15 Million USD | -619.46% |
| 2012 Q4 | -7.23 Million USD | 20.49% |
| 2012 Q3 | -9.09 Million USD | -55.94% |
| 2012 Q2 | -5.83 Million USD | 16.52% |
| 2012 Q1 | -6.98 Million USD | 8.13% |
| 2011 Q2 | -2.18 Million USD | 50.5% |
| 2011 FY | 5.61 Million USD | 111.23% |
| 2011 Q4 | -7.6 Million USD | -138.36% |
| 2011 Q3 | 19.83 Million USD | 1006.03% |
| 2011 Q1 | -4.42 Million USD | -115.37% |
| 2010 Q2 | -43.06 Million USD | -1650.73% |
| 2010 Q3 | -2.38 Million USD | 94.47% |
| 2010 Q4 | -2.05 Million USD | 13.79% |
| 2010 FY | -49.96 Million USD | -26.16% |
| 2010 Q1 | -2.46 Million USD | -737.81% |
| 2009 FY | -39.6 Million USD | -666.63% |
| 2009 Q4 | -293.63 Thousand USD | 98.83% |
| 2009 Q2 | -15.11 Million USD | -1956.84% |
| 2009 Q3 | -25 Million USD | -65.44% |
| 2009 Q1 | 814.12 Thousand USD | 166.15% |
| 2008 Q3 | -1.89 Million USD | -85.56% |
| 2008 Q2 | -1.01 Million USD | 0.7% |
| 2008 Q1 | -1.02 Million USD | 46.03% |
| 2008 Q4 | -1.23 Million USD | 34.9% |
| 2008 FY | -5.16 Million USD | -1.53% |
| 2007 FY | -5.08 Million USD | -7.32% |
| 2007 Q4 | -1.9 Million USD | -101.84% |
| 2007 Q3 | -941.77 Thousand USD | 17.0% |
| 2007 Q2 | -1.13 Million USD | -2.14% |
| 2007 Q1 | -1.11 Million USD | 14.27% |
| 2006 Q1 | -927.6 Thousand USD | 28.5% |
| 2006 FY | -4.74 Million USD | 3.81% |
| 2006 Q3 | -1.65 Million USD | -92.27% |
| 2006 Q2 | -861.46 Thousand USD | 7.13% |
| 2006 Q4 | -1.29 Million USD | 21.77% |
| 2005 FY | -4.92 Million USD | -39.2% |
| 2005 Q2 | -1.34 Million USD | -34.07% |
| 2005 Q4 | -1.29 Million USD | -1.0% |
| 2005 Q3 | -1.28 Million USD | 4.46% |
| 2005 Q1 | -1 Million USD | 56.09% |
| 2004 Q1 | -588.57 Thousand USD | -1.14% |
| 2004 Q2 | -429.87 Thousand USD | 26.96% |
| 2004 Q3 | -238.75 Thousand USD | 44.46% |
| 2004 Q4 | -2.28 Million USD | -856.54% |
| 2004 FY | -3.54 Million USD | -96.83% |
| 2003 Q1 | -478.56 Thousand USD | -190.57% |
| 2003 FY | -1.79 Million USD | 39.3% |
| 2003 Q4 | -581.94 Thousand USD | 11.71% |
| 2003 Q3 | -659.11 Thousand USD | -730.41% |
| 2003 Q2 | -79.37 Thousand USD | 83.41% |
| 2002 Q2 | -871.16 Thousand USD | -3.08% |
| 2002 Q1 | -845.12 Thousand USD | -31.07% |
| 2002 FY | -2.96 Million USD | -19920.27% |
| 2002 Q4 | -164.69 Thousand USD | 84.79% |
| 2002 Q3 | -1.08 Million USD | -24.29% |
| 2001 Q3 | 401.26 Thousand USD | 126.21% |
| 2001 FY | 14.95 Thousand USD | -99.19% |
| 2001 Q2 | 177.38 Thousand USD | 118.75% |
| 2001 Q1 | 81.08 Thousand USD | -88.79% |
| 2001 Q4 | -644.78 Thousand USD | -260.69% |
| 2000 Q4 | 723.36 Thousand USD | 43.5% |
| 2000 Q2 | 639.31 Thousand USD | 2479.99% |
| 2000 Q1 | -26.86 Thousand USD | -110.74% |
| 2000 FY | 1.83 Million USD | 144.08% |
| 2000 Q3 | 504.09 Thousand USD | -21.15% |
| 1999 Q3 | -1.68 Million USD | -20.0% |
| 1999 Q2 | -1.4 Million USD | -7.69% |
| 1999 Q4 | 250 Thousand USD | 114.88% |
| 1999 Q1 | -1.3 Million USD | 87.04% |
| 1999 FY | -4.17 Million USD | 85.11% |
| 1998 Q4 | -10.03 Million USD | -79.16% |
| 1998 Q1 | -7.1 Million USD | -21.44% |
| 1998 FY | -28.03 Million USD | -20.59% |
| 1998 Q2 | -5.3 Million USD | 25.35% |
| 1998 Q3 | -5.6 Million USD | -5.66% |
| 1997 Q2 | -7.2 Million USD | -53.19% |
| 1997 Q4 | -5.84 Million USD | -8.27% |
| 1997 Q3 | -5.4 Million USD | 25.0% |
| 1997 FY | -23.24 Million USD | -10.86% |
| 1997 Q1 | -4.7 Million USD | 46.4% |
| 1996 FY | -20.96 Million USD | -94.16% |
| 1996 Q4 | -8.76 Million USD | -108.79% |
| 1996 Q3 | -4.2 Million USD | 4.55% |
| 1996 Q2 | -4.4 Million USD | -22.22% |
| 1996 Q1 | -3.6 Million USD | -9.09% |
| 1995 Q3 | -2.5 Million USD | 0.0% |
| 1995 Q4 | -3.3 Million USD | -32.0% |
| 1995 FY | -10.8 Million USD | 0.0% |
| 1995 Q2 | -2.5 Million USD | 0.0% |
| 1995 Q1 | -2.5 Million USD | 10.71% |
| 1994 FY | -10.8 Million USD | -35.0% |
| 1994 Q1 | -2.6 Million USD | -4.0% |
| 1994 Q2 | -2 Million USD | 23.08% |
| 1994 Q3 | -3.3 Million USD | -65.0% |
| 1994 Q4 | -2.8 Million USD | 15.15% |
| 1993 Q4 | -2.5 Million USD | -13.64% |
| 1993 Q2 | -2 Million USD | -53.85% |
| 1993 Q3 | -2.2 Million USD | -10.0% |
| 1993 FY | -8 Million USD | -207.69% |
| 1993 Q1 | -1.3 Million USD | -62.5% |
| 1992 FY | -2.6 Million USD | 0.0% |
| 1992 Q3 | -900 Thousand USD | 0.0% |
| 1992 Q4 | -800 Thousand USD | 11.11% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 47.596% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -75.824% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 78.018% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 68.911% |
| Azitra, Inc. | -11.28 Million USD | -34.504% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -98.81% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -105.63% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 48.052% |
| CEL-SCI Corporation | -32.36 Million USD | 53.108% |
| iBio, Inc. | -24.9 Million USD | 39.065% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 29.363% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 23.243% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 33.846% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -57.439% |
| NanoViricides, Inc. | -8.29 Million USD | -82.986% |
| Oragenics, Inc. | -20.65 Million USD | 26.523% |
| BiomX Inc. | -26.16 Million USD | 42.003% |
| BiomX Inc. | -26.16 Million USD | 42.003% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 282.593% |
| Palatin Technologies, Inc. | -29.73 Million USD | 48.961% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 66.435% |